以仑伐替尼为基石的综合治疗——中晚期肝癌一线治疗新选择( 四 )


[2]中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].肿瘤综合治疗电子杂志 , 2020 , 6(2):55-85
[3]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)肝癌诊疗指南(2020版)[M].北京:人民卫生医学出版社,2020:59-60.
[4]HeM,LiQ,ZouR,etal.Sorafenibplushepaticarterialinfusionofoxaliplatin,fluorouracil,andleuc-ovorinvs.sorafenibaloneforhepatocellularcarcinomawithportalveininvasion:arandomizedclinicaltrial[J].JAMAOncol,2019,5(7):953-960.DOI:10.1001/jamaoncol.2019.0250.
[5]QicongMai,ZhiqiangMo,FengShi,etal.LenvatinibplushepaticarterialinfusionofmodifiedFOLFOXregimeinpatientswithadvancedhepatocellularcarcinoma.JClinOncol38:2020(suppl;abstre16603)
[6]卫材提供数据
[7]LYUN,KONGY,MUL,etal.Hepaticarterialinfusionofoxaliplatinplusfluorouracil/leucovorinvs.sorafenibforadvancedhepatocellularcarcinoma[J].JHepatol,2018,69(1):60-69.
[8]HEMK,LEY,LIQJ,etal.Hepaticarteryinfusionchemoth-erapyusingmFOLFOXversustransarterialchemoembolizationformassiveunresectablehepatocellularcarcinoma:aprospectivenon-randomizedstudy[J].ChinJCancer,2017,36(1):83
[9]ZhigangFu,XiaoweiLi,JiamingZhong,etal.Lenvatinibincombinationwithtransarterialchemoembolizationfortreatmentofunresectablehepatocellularcarcinoma(uHCC):aretrospectivecontrolledstudy[J].HepatolInt.2021;15(3):663-675
[10]《中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南》 , 中国医师协会介入医师分会中华医学杂志,2018,98(47):3811-3819.DOI:10.3760/cma.j.issn.0376-2491.2018.47.002
[11]RichardS.Finnetal.,AtezolizumabplusBevacizumabinUnresectableHepatocellularCarcinoma , NEnglJMed2020;382:1894-905.DOI:10.1056/NEJMoa1915745
[12]HepaticArterialInfusionchemotherapyoroxaliplatinplusfluorouracilversussorafenibinadvancedhepatocellularcarcinoma:abiomolecularexploratory,randomizedphase3trial , TheFOHAIC-1Study
*此文仅用于向医学人士提供科学信息 , 不代表本平台观点

以仑伐替尼为基石的综合治疗——中晚期肝癌一线治疗新选择
文章图片